⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

December 4, 2023The Lancet Diabetes & EndocrinologyOpen Access

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge Natalie Staplin KJ Mayne Christoph Wanner Julie Green SJ Hauske Jonathan Emberson David Preiss SYA Ng AJ Roddick Emily Sammons Dandan Zhu Michael Hill W. Grant Stevens Karl Wallendszus Susanne Brenner AK Cheung Zhihong Liu J Li LS Hooi Wenjun Liu Takashi Kadowaki Masaomi Nangaku Adeera Levin David Z.I. Cherney Aldo P. Maggioni Roberto Pontremoli Rajat Deo Shinichi Goto Xavier Rosselló Katherine R. Tuttle Dominik Steubl Daisy Massey Martin Landray Colin Baigent Richard Haynes WG Herrington S Abat Riaz Rahman Rizna Abdul Cader MI Abdul Hafidz MZ Abdul Wahab NK Abdullah Talal Abdulsamad Masanori Abe Nader G. Abraham Sarah Acheampong P Achiri JA Acosta A. Q. Adeleke Vicki Adell R Adewuyi-Dalton Nihad Adnan A Africano Mohsen Agharazii Frank G. Aguilar A Aguilera Movahedian Ahmad MK Ahmad NA Ahmad NH Ahmad NI Ahmad Norazinizah Ahmad Miswan H Ahmad Rosdi Iffat Ahmed Sofia B. Ahmed Sofia B. Ahmed Joan Aiello A. Aitken R AitSadi Sendogan Aker S Akimoto A Akinfolarin S. Akram Federico Alberici Christian Albert Leslie N. Aldrich M Alegata Lee Alexander S Alfaress Mohammad Alhadj Ali Ahmed Issam Ali Ahmed Issam Ali Radica Z. Alicic A Aliu Ricardo López Almaraz Rashid Almasarwah Jussara Carnevale de Almeida Alessia Aloisi Laith Al‐Rabadi Mark Dominik Alscher Pedro Álvarez Bader Al-Zeer Mora Amat Christopher S. Ambrose Hany Ammar Yu An L Andriaccio Kwame Ansu A Apostolidi

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Judge et al. (2023) studied this question.

synapsesocial.com/papers/69dbe35f387cf70698689215 https://doi.org/10.1016/s2213-8587(23)00322-4

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Empagliflozin in Patients with Chronic Kidney DiseaseRCT · 2022 · 2,875 citations
2Dapagliflozin in Patients with Chronic Kidney DiseaseOriginal Research · 2020 · 5,615 citations
3Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyRCT · 2019 · 6,368 citations
4Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trialsRCT · 2022 · 1,048 citations
5Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trialRCT · 2022 · 111 citations
6The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY studyOriginal Research · 2018 · 237 citations
7A New Equation to Estimate Glomerular Filtration RateCross-Sectional Study · 2009 · 25,620 citations
8Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical TrialPrognostic Study · 1975 · 2,355 citations
9Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trialsENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2021
10Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialThe Lancet Diabetes & Endocrinology · 2021

More from The Lancet Diabetes & Endocrinology

More from University of Oxford

More from Heidelberg University

More from University of Utah

More from Medical Research Council

More from University Hospital Heidelberg

More from Clinical Research Institute

More from Boehringer Ingelheim (Germany)